Navigation Links
MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
Date:2/21/2008

WARREN, N.J., Feb. 21 /PRNewswire/ -- MonoSol Rx, a drug delivery company specializing in dissolving thin film pharmaceutical products, today announced that it has successfully completed a pilot clinical study for its thin film formulation of ondansetron, a selective 5-HT3 receptor antagonist used in the prevention and treatment of nausea and vomiting.

MonoSol Rx's thin film formulation of ondansetron was studied against GlaxoSmithKline's Zofran ODT(R) product. Based on the results of the study, MonoSol Rx is moving immediately to pivotal trials to enable drug submissions both in the US and Europe. The Company expects to file with the appropriate regulatory authorities in 2008.

A. Mark Schobel, president and chief executive officer of MonoSol Rx, stated, "Successful completion of this pilot study marks an important step towards commercializing what we believe is a product with significant benefits over existing formulations of ondansetron. Our thin film formulation of ondansetron is particularly well suited for the target patient population because individuals who are prescribed the drug often have difficulty swallowing due to extreme nausea caused by chemotherapy, radiotherapy and surgical procedures. Incorporating ondansetron into a great-tasting thin film formulation that dissolves quickly in the mouth allows the drug to be easily administered without water, making it more palatable and less likely to cause additional discomfort."

MonoSol Rx's formulation of ondansetron is a new oral formulation expected to be introduced to the market next year. Its indications are the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV), prevention of nausea and vomiting associated with radiotherapy, and prevention of Post-Operative Nausea and Vomiting (PONV).

MonoSol Rx's thin film technology utilizes strategic and proprietary intellectual property that ensures predictable in-vivo performance and provides superior characteristics over
'/>"/>

SOURCE MonoSol Rx
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)... Highlights Include:, -- Results demonstrating ... clinically meaningful extension of progression-fr...zumab to attack both the inside and,outside of the...ckade, -- Data demonstrating activity of TYKERB a...tiple lines of trastuzumab and chemotherapy, LOND...
(Date:5/16/2008)... - ANX-530 Demonstrates Statistically Significant ...fety Observations, - Abstract to be published in 2... Clinical Oncology, SAN DIEGO, ...uticals,Inc. (Amex: ANX ) announced today that, ... ANX-530 demonstrated a statistically significant ...
(Date:5/15/2008)... - First in human clinical data highlight safety ...h advanced solid tumors -, BRISBANE, Calif., May ...ly held biopharmaceutical company developing novel...rting its lead PARP inhibitor, BSI-201, will,be pr...ncology annual,meeting in Chicago., Findings will...
(Date:5/15/2008)... KENILWORTH, N.J., May 15 /PRNewswire-FirstCall/...eader in advancing the science and treatment of,ch... today that data from,several clinical studies wit...L(R) (ribavirin, USP) combination therapy, as well... HCV protease inhibitor, will be presented at,the ...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7Family history of alcoholism affects response to drug used to treat heavy drinking 1563 1Family history of alcoholism affects response to drug used to treat heavy drinking 1563 2New study shows fish respond quickly to changes in mercury deposition 452 1New study shows fish respond quickly to changes in mercury deposition 452 2New study shows fish respond quickly to changes in mercury deposition 452 3 3Ci 3ECosby 3C i 3E Star Tackles a Silent Heart Threat 1557 1 3Ci 3ECosby 3C i 3E Star Tackles a Silent Heart Threat 1557 2 3Ci 3ECosby 3C i 3E Star Tackles a Silent Heart Threat 1557 3 3Ci 3ECosby 3C i 3E Star Tackles a Silent Heart Threat 1557 4IsoTis Integra Merger 678 1IsoTis Integra Merger 678 2IsoTis Integra Merger 678 3IsoTis Integra Merger 678 4IsoTis Integra Merger 678 5
...RN, Pa.--(BUSINESS WIRE)--Mar 7, 2007 - Gemin X,an...e version of,the journal Blood demonstrated that i...tent cytotoxic responses against,patient-derived m...,enhanced anti-myeloma effects when used as a comb...ifically designed to inhibit all,relevant members ...
...NESS WIRE)--Mar 7, 2007 - Advanced Viral,Research ...cal,company, announced today that new information ... 2007 Proceedings of the American,Society of Clini...lication will be distributed to the nearly 25,000 ...ar,s meeting in Chicago on,June 1-5., Based on rec...
Other Medicine Technology:Gemin X Announces Publication of Preclinical Data of GX15-070 in,Multiple Myeloma in Blood 2American Society of Clinical Oncology (ASCO) Accepts New Data on,AVR118 for Publication in 2007 Abstract Book 2American Society of Clinical Oncology (ASCO) Accepts New Data on,AVR118 for Publication in 2007 Abstract Book 3
(Date:5/16/2008)...hy Back Acquires Rival JoAnne,s Bed & Back; Merger... Company Owned Back Retail Chain, LORTON, Va., Ma...,company whose focus on home and workplace back we...ed all substantial assets of its rival,JoAnne,s B...division,claimed 2007 revenues of $40million. JoAn...
(Date:5/16/2008)NEW YORK, May 16 /PRNewswire/ -- There,s more to a healthy mouth than,flashing a set of pearly whites. Here,s the scoop on America,s oral care,habits - and what it means for our overall health.,
(Date:5/16/2008)...rs could report side effects, but critics want age...ay 16 (HealthDay News) -- Direct-to-consumer drug ... number that would allow consumers to report adver...day. , The experts serve on a panel that advise...e numbers are already mandated by the FDA for prin...
(Date:5/16/2008)...long Campaign to Emphasize the Importance of Oral ...wswire/ -- National dental insurer United,Concordi...llaboration,between Oral Health America and the Br...rtance of oral health to overall health. Beginning...ted States for the first time,making it the large...
Breaking Medicine News(10 mins):Health News:The Back Wars Come to a Close 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3Health News:United Concordia Dental Celebrates National Smile Month 2
...essfully performed on an eight-month-old Egyptian ...m Ibrahim was initially evaluated by a team of pae...l and was diagnosed to have complete atrio-ventric...s -- a condition wherein there are holes in the up...
...itiated a two-year study to measure the wellbeing ...nce with respect to// schooling, education and oth...ble impact on childhood, will be studied, to ascer...tiative is headed by Prof Richard Layard, a former...
...hird of the country's children in a five-year prog...n children in 1,301 counties of central and wester...inst hepatitis B, said Jiang Zuojun, the Vice-Mini...th officials will have to quicken their pace to re...
...re suffering due to cuts in NHS expenditure, as co...y says.// The study, which has been commissioned...ered that almost seven out of 10 local authorities...it, have suffered. Cost-cutting measures of the N...
Other Medicine News:
Clearview C. Diff A is a one-step test for the direct qualitative detection of Clostridium difficile toxin A from fecal samples.
ThyroTest TSH is a rapid, qualitative test for hypothyroidism screening in adults.
...is one of the easiest tests to run on the market t...th no hands-on time. Critical care instructions ca...g the pediatrician's office and valuable informati...help control the spread of RSV infections. Now the...
The BinaxNOW Influenza A & B Test simplifies rapid influenza testing. The easiest flu test on the market just got easier with accurate differentiation between influenza A and influenza B using one si
Medicine Products: